Commerzbank Aktiengesellschaft FI Has $250,000 Position in ResMed Inc. (NYSE:RMD)

Commerzbank Aktiengesellschaft FI grew its holdings in shares of ResMed Inc. (NYSE:RMD) by 17.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,089 shares of the medical equipment provider’s stock after acquiring an additional 165 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in ResMed were worth $250,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. True Wealth Design LLC grew its holdings in ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 110 shares during the period. Ashton Thomas Securities LLC acquired a new stake in ResMed during the 3rd quarter worth about $34,000. BankPlus Trust Department acquired a new stake in ResMed during the 4th quarter worth about $44,000. Rosenberg Matthew Hamilton acquired a new stake in ResMed during the 4th quarter worth about $54,000. Finally, Capital Performance Advisors LLP acquired a new stake in ResMed during the 3rd quarter worth about $60,000. 54.98% of the stock is currently owned by institutional investors and hedge funds.

ResMed Price Performance

Shares of NYSE RMD opened at $223.76 on Thursday. ResMed Inc. has a fifty-two week low of $172.19 and a fifty-two week high of $263.05. The stock has a market cap of $32.86 billion, a price-to-earnings ratio of 26.42, a PEG ratio of 1.53 and a beta of 0.70. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The firm’s 50-day simple moving average is $236.90 and its 200 day simple moving average is $239.90.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. As a group, research analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.95%. ResMed’s dividend payout ratio is currently 25.03%.

Analyst Ratings Changes

Several brokerages have recently commented on RMD. UBS Group upgraded ResMed from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 31st. Piper Sandler raised their target price on ResMed from $252.00 to $260.00 and gave the company a “neutral” rating in a research note on Friday, January 31st. Citigroup upgraded ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday. The Goldman Sachs Group began coverage on ResMed in a research note on Thursday, January 16th. They issued a “buy” rating for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Friday, January 31st. One research analyst has rated the stock with a sell rating, five have given a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, ResMed presently has an average rating of “Moderate Buy” and an average target price of $243.82.

Insiders Place Their Bets

In related news, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $236.77, for a total value of $1,896,290.93. Following the sale, the chief executive officer now owns 455,472 shares of the company’s stock, valued at approximately $107,842,105.44. The trade was a 1.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the sale, the director now directly owns 77,218 shares in the company, valued at $18,695,249.98. This trade represents a 2.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 19,186 shares of company stock valued at $4,541,226 in the last 90 days. 0.71% of the stock is currently owned by corporate insiders.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.